Life Interrupted – Nick’s Fight Against Aplastic Anemia
Person's Name:
Nick Karavite
Here is Nick's story, as told by his mom, Pamela Karavite
Bone Marrow Disease(s):
Content source:
patient
Hereditary MDS
Lucy Godley, MD, PhD, (UChicago Medicine) discusses the connection between heredity and MDS. While MDS is most often not inherited, there are some genetic mutations and other genetic conditions that can lead to a diagnosis of MDS.
Ivana Gojo, MD
Gojo, Ivana
Professor of Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore.
Online Profile:
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Key Points
In patients with RR-AML, venetoclax combination therapy resulted in responses in 31% of patients and a median OS of 6.1 months.
NPM1 mutations predicted higher response rates; adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 predicted worse OS.
Scientists discover two unique subtypes of a prominent mutation in patients with AML
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with
Jane Liesveld, MD
Liesveld, Jane
Hematologist
Strong Memorial Hospital
Online Profile:
Robert Hasserjian, MD
Hasserjian, Robert
Director, Hematopathology Fellowship Program
Massachusetts General Hospital
Dr. Hasserjian's clinical work and research focus on myeloid neoplasia. He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.
Online Profile:
TP53 Modifier Impresses in Early MDS/AML Study
A drug that targets a common mutation in
Azacitidine Maintenance Fails to Improve Post-Transplant Outcomes in High-Risk AML and MDS
Sandrine Niyongere, MD
Niyongere, Sandrine
Assistant Professor of Medicine
University of Maryland Greenebaum Comprehensive Cancer Center